| Q38150728 | A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts |
| Q36290698 | A review of clinical experience with newer antifungals in children |
| Q41855352 | An Outbreak of Neonatal Candidemia Due to Non-albicans Candida Species in a Resource Constrained Setting of Uttarakhand State, India |
| Q37266338 | Antifungal Activity of Cinnamon Oil and Olive Oil against Candida Spp. Isolated from Blood Stream Infections |
| Q48226991 | Antimicrobial synergism and cytotoxic properties of Citrus limon L., Piper nigrum L. and Melaleuca alternifolia (Maiden and Betche) Cheel essential oils. |
| Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
| Q37015976 | Candida endophthalmitis: focus on current and future antifungal treatment options |
| Q42759519 | Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex |
| Q36904887 | Candidemia in the in-patient setting: treatment options and economics |
| Q35947465 | Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia |
| Q34648425 | Clinical efficacy and health implications of inconsistency in different production batches of antimycotic drugs in a developing country |
| Q42408609 | Clinical significance of azole antifungal drug cross-resistance in Candida glabrata |
| Q42025836 | Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. an |
| Q42910172 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates |
| Q41969487 | Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use |
| Q41071178 | Determination of MICs of aminocandin for Candida spp. and filamentous fungi |
| Q37036246 | Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr |
| Q37283450 | Emergence of non-albicans Candida species in neonatal candidemia |
| Q33851338 | Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, India |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q43701370 | Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome |
| Q41855232 | Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon |
| Q46119145 | Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. |
| Q92430011 | Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161 |
| Q37159433 | In vitro activity of origanum vulgare essential oil against candida species |
| Q37631486 | Invasive candidiasis in pediatric intensive care units |
| Q37643057 | Invasive fungal infections in the ICU. |
| Q46876288 | Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values |
| Q38285488 | Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases |
| Q51149332 | Jjj1 Is a Negative Regulator of Pdr1-Mediated Fluconazole Resistance in Candida glabrata. |
| Q37327089 | Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy |
| Q36314322 | Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp |
| Q35690728 | Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. |
| Q36728707 | Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India |
| Q36825717 | Nosocomial fungal infections: epidemiology, diagnosis, and treatment |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q37756116 | Pharmacokinetic/pharmacodynamic profile of posaconazole |
| Q42515150 | Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection |
| Q89347255 | Prevalence of candidemia and associated candida subtypes following severe sepsis in non-neutropenic critically ill patients |
| Q36172242 | Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 |
| Q27681900 | Propargyl-Linked Antifolates are Dual Inhibitors of Candida albicans and Candida glabrata |
| Q90426424 | Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata |
| Q39899742 | Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. |
| Q35913918 | Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion test |
| Q28830247 | Sensitivity of clinical isolates of Candida to essential oils from Burseraceae family |
| Q34856747 | Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China |
| Q51186546 | The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. |
| Q81083934 | The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis |
| Q44863417 | The role of voriconazole in the treatment of emerging mycoses |
| Q41971254 | To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. |
| Q36521993 | Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole |
| Q34058180 | UPC2A is required for high-level azole antifungal resistance in Candida glabrata |
| Q42071108 | Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods |
| Q43008903 | Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. |
| Q35067016 | Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program |
| Q37374850 | Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. |
| Q36729599 | Voriconazole : a review of its use in the management of invasive fungal infections |
| Q42625550 | Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution |
| Q33738435 | Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods |
| Q83392396 | [Antifungal therapy update: new drugs and medical uses] |
| Q31129662 | [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. |